Equities research analysts expect AtriCure Inc. (NASDAQ:ATRC) to announce ($0.25) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for AtriCure’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.37). AtriCure posted earnings of ($0.24) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.2%. The company is expected to announce its next quarterly earnings results on Thursday, November 7th.

According to Zacks, analysts expect that AtriCure will report full year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.97) to ($0.70). For the next financial year, analysts expect that the company will post earnings of ($0.74) per share, with EPS estimates ranging from ($1.11) to ($0.40). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover AtriCure.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. AtriCure had a negative net margin of 9.46% and a negative return on equity of 13.06%. The company had revenue of $58.90 million for the quarter, compared to analysts’ expectations of $57.76 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. AtriCure’s quarterly revenue was up 13.7% on a year-over-year basis.

ATRC has been the topic of several research reports. BTIG Research restated a “buy” rating and issued a $35.00 price target on shares of AtriCure in a research report on Tuesday, August 13th. BidaskClub cut shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Thursday, September 12th. Zacks Investment Research cut shares of AtriCure from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Needham & Company LLC set a $39.00 price target on shares of AtriCure and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Piper Jaffray Companies set a $40.00 price target on shares of AtriCure and gave the stock a “buy” rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $36.57.

ATRC traded down $0.20 during trading hours on Wednesday, hitting $25.80. The company’s stock had a trading volume of 174,094 shares, compared to its average volume of 233,381. The business’s 50-day moving average price is $27.69 and its 200-day moving average price is $29.04. AtriCure has a 12 month low of $22.57 and a 12 month high of $36.49. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -27.45 and a beta of 0.33. The company has a current ratio of 3.72, a quick ratio of 3.10 and a debt-to-equity ratio of 0.15.

In other AtriCure news, CEO Michael H. Carrel sold 1,454 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $33.00, for a total transaction of $47,982.00. Following the transaction, the chief executive officer now owns 637,557 shares in the company, valued at $21,039,381. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Douglas J. Seith sold 48,804 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.63, for a total transaction of $1,250,846.52. Following the transaction, the chief operating officer now owns 208,281 shares in the company, valued at approximately $5,338,242.03. The disclosure for this sale can be found here. Insiders have sold 75,258 shares of company stock worth $2,098,829 in the last quarter. Company insiders own 8.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Assetmark Inc. increased its position in AtriCure by 109.7% during the second quarter. Assetmark Inc. now owns 975 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 510 shares during the last quarter. Virginia Retirement Systems ET AL grew its holdings in shares of AtriCure by 4.7% in the second quarter. Virginia Retirement Systems ET AL now owns 17,900 shares of the medical device company’s stock worth $534,000 after purchasing an additional 800 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of AtriCure by 114.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,597 shares of the medical device company’s stock worth $48,000 after purchasing an additional 853 shares during the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of AtriCure by 6.4% in the second quarter. Parametric Portfolio Associates LLC now owns 16,738 shares of the medical device company’s stock worth $499,000 after purchasing an additional 1,006 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of AtriCure by 3.4% in the first quarter. Rhumbline Advisers now owns 48,738 shares of the medical device company’s stock worth $1,306,000 after purchasing an additional 1,594 shares during the last quarter. Institutional investors and hedge funds own 88.85% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

Featured Article: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on AtriCure (ATRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.